Generic Nexlizet Availability

Last updated on Jun 11, 2025.

Nexlizet is a brand name of bempedoic acid/ezetimibe, approved by the FDA in the following formulation(s):

NEXLIZET (bempedoic acid; ezetimibe - tablet;oral)

• Manufacturer: ESPERION THERAPS INC
  Approval date: February 26, 2020
  Strength(s): 180MG;10MG ^[RLD]

Is there a generic version of Nexlizet available?

No. There is currently no therapeutically equivalent version of Nexlizet available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nexlizet. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
  Patent 10,912,751
  Issued: February 9, 2021
  Inventor(s): Newton Roger Schofield & Rosenberg Noah Laban & MacDougall Diane Elaine
  Assignee(s): Esperion Therapeutics, Inc.
  

  Disclosed herein are compositions comprising fixed doses of ETC-1002 and Ezetimibe. Also disclosed herein are methods for using fixed doses of ETC-1002 and Ezetimibe. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia in a subject.

  Patent expiration dates:

  • March 14, 2036
    
    ✓ 
    Patent use: A METHOD OF TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE BY DECREASING THE LEVEL OF LDL-C USING A FIXED DOSE COMBINATION OF 180 MG BEMPEDOIC ACID AND 10 MG EZETIMIBE
  • March 14, 2036
    
    ✓ 
    Patent use: A METHOD OF LOWERING LDL-C OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA USING A FIXED-DOSE COMBINATION OF 180 MG BEMPEDOIC ACID AND 10 MG EZETIMIBE
• Methods of making bempedoic acid and compositions of the same
  Patent 11,613,511
  Issued: March 28, 2023
  Inventor(s): Copp; Richard et al.
  Assignee(s): Esperion Therapeutics, Inc. (Ann Arbor, MI)
  

  The invention provides methods of preparing 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and methods of making a pharmaceutical material comprising a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid. Also provided are compositions and pharmaceutical materials including a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid as well as methods of treating various diseases and conditions using the compositions and pharmaceutical materials.

  Patent expiration dates:

  • June 19, 2040
    
    ✓ 
    Drug substance
• Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
  Patent 11,744,816
  Issued: September 5, 2023
  Inventor(s): Newton; Roger Schofield et al.
  Assignee(s): Esperion Therapeutics, Inc. (Ann Arbor, MI)
  

  Disclosed herein are compositions comprising fixed doses of ETC-1002 and Ezetimibe. Also disclosed herein are methods for using fixed doses of ETC-1002 and Ezetimibe. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia in a subject.

  Patent expiration dates:

  • March 14, 2036
    
    ✓ 
    Patent use: A METHOD OF TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE BY DECREASING THE LEVEL OF LDL-C USING 180 MG BEMPEDOIC ACID AND 10 MG EZETIMIBE
  • March 14, 2036
    
    ✓ 
    Patent use: A METHOD OF LOWERING LDL-C OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA USING 180 MG BEMPEDOIC ACID AND 10 MG EZETIMIBE
• Methods of making bempedoic acid and compositions of the same
  Patent 11,760,714
  Issued: September 19, 2023
  Inventor(s): Copp; Richard et al.
  Assignee(s): Esperion Therapeutics, Inc. (Ann Arbor, MI)
  

  The invention provides methods of preparing 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and methods of making a pharmaceutical material comprising a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid. Also provided are compositions and pharmaceutical materials including a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid as well as methods of treating various diseases and conditions using the compositions and pharmaceutical materials.

  Patent expiration dates:

  • June 19, 2040
    
    ✓ 
    Drug product
• Methods of making bempedoic acid and compositions of the same
  Patent 11,926,584
  Issued: March 12, 2024
  Inventor(s): Copp; Richard et al.
  Assignee(s): Esperion Therapeutics, Inc. (Ann Arbor, MI)
  

  The invention provides methods of preparing 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and methods of making a pharmaceutical material comprising a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid. Also provided are compositions and pharmaceutical materials including a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid as well as methods of treating various diseases and conditions using the compositions and pharmaceutical materials.

  Patent expiration dates:

  • June 19, 2040
    
    ✓ 
    Patent use: A METHOD OF LOWERING LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) IN A HUMAN PATIENT IN NEED THEREOF COMPRISING ADMINISTRATION OF BEMPEDOIC ACID ALONE OR IN COMBINATION WITH OTHER LIPID LOWERING THERAPIES
• Hydroxyl compounds and compositions for cholesterol management and related uses
  Patent 7,335,799
  Issued: February 26, 2008
  Inventor(s): Dasseux; Jean-Louis Henri et al.
  Assignee(s): Esperion Therapeutics, Inc. (Ann Arbor, MI)
  

  The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

  Patent expiration dates:

  • December 3, 2030
    
    ✓ 
    Drug substance

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:

  • February 21, 2025 - NEW CHEMICAL ENTITY
  • March 22, 2027 - EXPANDED INDICATION FOR USE AS AN ADJUNCT TO DIET, ALONE OR IN COMBINATION WITH OTHER LDL-C LOWERING THERAPIES, TO REDUCE LDL-C IN ADULTS WITH PRIMARY HYPERLIPIDEMIA, INCLUDING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)
  • March 22, 2027 - TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND CORONARY REVASCULARIZATION IN ADULTS WHO ARE UNABLE TO TAKE RECOMMENDED STATIN THERAPY (INCLUDING THOSE NOT TAKING A STATIN) WITH ESTABLISHED CARDIOVASCULAR DISEASE (CVD), OR AT HIGH RISK FOR A CVD EVENT BUT

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer